At a glance
- Originator Pfizer
- Class Oximes
- Mechanism of Action Muscarinic M1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cognition disorders
Most Recent Events
- 25 Sep 2006 Discontinued - Phase-II for Cognition disorders in USA (unspecified route)
- 15 Nov 2000 Phase-II clinical trials for Cognition disorders in USA (Unknown route)
- 01 Sep 2000 No-Development-Reported for Cognition disorders in USA (Unknown route)